Food allergy has a second lane now

Food allergy treatment has lived inside a one-modality box for a generation: avoid the trigger, carry an EpiPen, and if a patient will accept the trade-offs, grind out years of oral immunotherapy. New Scientist's reporting on a Boston Children's pilot points at a second option taking shape, one that re-shapes tolerance by re-seeding the gut's regulatory machinery rather than by dosing the allergen itself.

Fifteen adults, no blinding, no control arm, and an open-label design that John Ziegler at the University of New South Wales has already flagged as unable to rule out a placebo effect. The result is still concrete. Six of the 15 could tolerate more peanut at four months, most reaching the equivalent of one whole peanut and one reaching four. Others dropped out or never had the donor strain colonize, which is itself informative: the mechanism is microbial, not pharmacological, so a miss on colonization reads as a miss on the treatment, not as a participant failure.

The repeatable frame is the modality split. Oral immunotherapy asks the immune system to learn the allergen in escalating doses. Microbial therapy asks the gut to host a new conversation with it, working through a regulatory T-cell MyD88/ROR-γt pathway that preclinical work has already mapped. The two approaches can be sequenced or combined. Rachid's team has moved the question into a randomized placebo-controlled pediatric trial in 12 to 17 year olds, the design that will actually settle whether the second modality holds.